Sara Lodi
Profiles

Sara Lodi, PhD

Associate Professor, Biostatistics - Boston University School of Public Health

617-358-2705
slodi@bu.edu
Crosstown Center
View Full Profile at BUMC

Biography

Sara Lodi is an Associate Professor of Biostatistics at the Boston University School of Public Heath. She obtained her PhD in Medical Statistics at the London School of Hygiene and Tropical Medicine in 2009, UK. Her research focuses on causal inference methods for observational studies using big data, methods for causal inference to improve the statistical analysis of clinical trials, and the reconciliation of results from clinical trials and observational studies. She leads cutting edge research that focuses on the translation of methodologic advancements in causal inference into actionable findings for real world public health research questions, mainly in the areas of infectious diseases (HIV, hepatitis C, tuberculosis) and substance use disorder. She has published many articles on behalf of large international collaborations of HIV cohorts such as CASCADE, COHERE and the HIV-CAUSAL, and HepCAUSAL collaborations. She’s been an instructor for both BS851 Applied Statistics in Clinical Trials and BS807 Applied Causal Inference in Health Research.

Education

  • London School of Hygiene & Tropical Medicine, PhD Field of Study: Statistics
  • University of Southampton, MSc Field of Study: Statistics
  • Univ of Bologna, BA Field of Study: Statistics

Websites

Classes Taught

  • SPHBS807
  • SPHBS851

Publications

  • Published on 5/28/2026

    Rossi SL, Cheng DM, Sereda Y, Truong V, Carroll JJ, Kiriazova T, Lodi S, Michals A, Raj A, Krupitsky E, Lioznov D, Samet JH, Lunze K. COVID-19 pandemic-related stress and substance use behaviors among people with HIV - a mixed method analysis. PLoS One. 2026; 21(5):e0349567. PMID: 42207818.

     Read At: PubMed
  • Published on 5/20/2026

    van Santen DK, Chalouni M, Berenguer J, Jarrin I, Miró JM, Klein MB, Young J, Torgersen J, Rentsch CT, Gill MJ, Epstein RL, Nunes D, Surial B, Rauch A, Touloumi G, Papadopoulos A, Wittkop L, Gilbert C, Leleux O, van der Valk M, Boyd A, Monforte AD, Puoti M, Zangerle R, Gisinger M, Logan RW, Rein S, Hernán MA, Lodi S. Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV. Clin Infect Dis. 2026 May 20; 82(5):e942-e950. PMID: 41253696.

     Read At: PubMed
  • Published on 4/27/2026

    Hansford HJ, McAuley JH, Swanson SA, Islam N, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sterne JAC, Sharp MK, Jones MD, Stuart EA, Lee H, Hernán MA, Cashin AG. The TARGET guideline for reporting observational studies of interventions. Nat Med. 2026 Apr 27. PMID: 42045579.

     Read At: PubMed
  • Published on 3/2/2026

    Socias ME, Lei J, Zhou V, Anand R, Cui Z, Penta S, Larochelle M, Lodi S, Fairbairn N. Slow-Release Oral Morphine vs Methadone for Opioid Use Disorder in the Fentanyl Era. JAMA Netw Open. 2026 Mar 02; 9(3):e262970. PMID: 41874507.

     Read At: PubMed
  • Published on 1/19/2026

    Pan S, Patil P, Weinberg J, Lodi S, LaValley MP. Generalized pairwise comparisons using pseudo-observations for time-to-event censored data in a randomized controlled trial setting. Stat Methods Med Res. 2026 Feb; 35(2):413-425. PMID: 41549701.

     Read At: PubMed
  • Published on 10/21/2025

    Degirmenci HB, Peloquin CE, Westerland M, Lodi S, Machado PM, Jafarzadeh SR, Neogi T, Gensler LS, Dubreuil M, Liew JW. Trends in Opioid Prescriptions in Individuals With Axial Spondyloarthritis in the United States and United Kingdom in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data. Arthritis Care Res (Hoboken). 2026 Jan; 78(1):66-75. PMID: 40977482.

     Read At: PubMed
  • Published on 9/23/2025

    Cashin AG, Hansford HJ, Hernán MA, Swanson SA, Lee H, Jones MD, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Islam N, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sharp MK, Sterne JAC, Stuart EA, McAuley JH. Transparent Reporting of Observational Studies Emulating a Target Trial-The TARGET Statement. JAMA. 2025 Sep 23; 334(12):1084-1093. PMID: 40899949.

     Read At: PubMed
  • Published on 9/4/2025

    Weinstein ZM, Magane KM, Lodi S, Doeleman D, Ventura AS, Bazzi AR, Davoust M, Shea MG, Chen CA, Cheng A, Theisen J, Blakemore S, Saitz R. Associations between COVID impact domains and time to buprenorphine treatment disengagement. Am J Drug Alcohol Abuse. 2025; 51(6):776-785. PMID: 40906491.

     Read At: PubMed
  • Published on 9/3/2025

    Cashin AG, Hansford HJ, Hernán MA, Swanson SA, Lee H, Jones MD, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Islam N, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sharp MK, Sterne JAC, Stuart EA, McAuley JH. Transparent reporting of observational studies emulating a target trial: the TARGET Statement. BMJ. 2025 Sep 03; 390:e087179. PMID: 40903028.

     Read At: PubMed
  • Published on 3/19/2025

    Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Aug; 120(8):1634-1645. PMID: 40104887.

     Read At: PubMed

View 92 more publications:View Full Profile at BUMC

News & In the Media

View all profiles